Tirabrutinib rechallenge case report

4 evidence topics · 1 source

Objective

Location and study date

No evidence found.

Study design

Eligibility criteria

Not applicable.

Treatment

Reported tirabrutinib dosage

“tirabrutinib (480 mg/day)” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using clinical response as an observed outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

No evidence found.

Baseline characteristics

Presentation

“A 75-year-old man presented with gait disturbance, dysarthria, and ataxia.” (opens the source at this quote in a new tab)

Efficacy results

Rechallenge response duration

“A third recurrence led to a tirabrutinib rechallenge, and remission lasted five months.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

Summary

A single participant experienced five months of remission after tirabrutinib rechallenge. This observation does not establish the probability of response to rechallenge, an optimal retreatment interval, or comparative benefit.